Kiniksa Pharmaceuticals International (KNSA) Finished Goods (2021 - 2023)

Kiniksa Pharmaceuticals International (KNSA) has reported Finished Goods for 3 consecutive years, with $12.9 million the latest figure, recorded in Q4 2023.

• For the quarter ending Q4 2023, Finished Goods fell 15.85% year-over-year to $12.9 million; the trailing twelve-month figure through Dec 2023 stood at $12.9 million (down 15.85% YoY), and the FY2023 full-year result was $12.9 million, down 15.85% from the prior year.
• Finished Goods advanced to $12.9 million in Q4 2023 per KNSA's latest filing, from $12.2 million in the prior quarter.
• Across five years, Finished Goods topped out at $19.9 million in Q2 2022 and bottomed at $1.4 million in Q3 2021.
• Historically, Finished Goods has averaged $10.4 million across 3 years, with a median of $12.5 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Finished Goods surged 927.48% in 2022, then declined 24.22% in 2023.
• Over 3 years, Finished Goods stood at $3.7 million in 2021, then jumped by 315.97% to $15.3 million in 2022, then slipped by 15.85% to $12.9 million in 2023.
• According to Business Quant data, Finished Goods over the past three periods registered $12.9 million, $12.2 million, and $17.3 million for Q4 2023, Q3 2023, and Q2 2023 respectively.